The VITROS® SARS-CoV-2 Antigen test is a random-access, high-throughput test for the accurate detection of SARS-CoV-2 infection. Designed for performance, the VITROS® SARS-CoV-2 Antigen test targets the Nucleocapsid Protein, the most abundant protein of the SARS-CoV-2 virus, optimizing test sensitivity. Instrument throughput targeted for up to 130 tests per hour on-board instrument. Now available on the VITROS® XT 7600 and 5600 Integrated Systems, and the VITROS® 3600 Immunodiagnostic System.
FDA status: Emergency Use Authorization (EUA)
Time to first result: 48 minutes
Sample Volume: Pre-Extracted 400 μL
Sample Volume: Post-Extraction 80 μL not including dead volume
Calibration Interval: Lot change or every 28 days
Reagent on-board stability: Up to 4 weeks
Reagent Type: Liquid Ready to Use
Specimens Recommended: Nasopharyngeal (NP)*
Quality Controls: Positive and Negative
*Ortho continues to validate other specimen types. See Instructions for Use for transport media validated by Ortho.